Clinical Trial: Telavancin (TD 6424, ARBELIC™) for Treatment of Uncomplicated Staphylococcus aureus Bacteremia

This study is currently recruiting patients.

Sponsored by: Theravance
Information provided by: Theravance

Purpose

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

Condition Treatment or Intervention Phase
Gram-Positive Bacterial Infections
 Drug: Telavancin (TD-6424, Arbelic)
Phase II

MedlinePlus related topics:  Bacterial Infections

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous ARBELIC™ (TD 6424) for Treatment of Uncomplicated Staphylococcus aureus Bacteremia

Further Study Details: 

Expected Total Enrollment:  60

Study start: June 2003

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Uncomplicated Staphylococcus aureus bacteremia that is healthcare associated.

Location and Contact Information


Michigan
      William Beaumont Hospital, Royal Oak,  Michigan,  48073,  United States; Recruiting
Christopher F. Carpenter, MD  248-551-7941 

More Information

Study ID Numbers:  I6424-203a; ASSURE
Record last reviewed:  October 2004
Last Updated:  October 13, 2004
Record first received:  June 9, 2003
ClinicalTrials.gov Identifier:  NCT00062647
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources